COVID-19 related patent filings increased in the pharmaceutical industry in Q2 2023
Notably, the number of Covid-19-related patent applications in the pharmaceutical industry was 663 in Q2 2023, versus 536 in the prior quarter.
The top five companies accounted for 4% of patenting activity
Analysis of patenting activity by companies shows that F. Hoffmann-La Roche filed the most Covid-19 patents within the pharmaceutical industry in Q2 2023. The company filed 7 Covid-19-related patents in the quarter, compared with 2 in the previous quarter. It was followed by Tsinghua University with 6 Covid-19 patent filings, Enanta Pharmaceuticals (5 filings), and Shanghai Institute of Materia Medica Chinese Academy of Sciences (4 filings) in Q2 2023.
Patenting activity was driven by the US with a 44% share of total patent filings
The largest share of Covid-19 related patent filings in the pharmaceutical industry in Q2 2023 was in the US with 44%, followed by China (10%) and Japan (8%). The share represented by the US was 35% higher than the 9% share it accounted for in Q1 2023.
To further understand GlobalData’s analysis on COVID-19 Cross-Sector Impact – Thematic Research buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
Source link
#COVID19 #related #patent #filings #increased #pharmaceutical #industry
